Emergent BioSolutions Inc

EBS

Company Profile

  • Business description

    Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

  • Contact

    300 Professional Drive
    GaithersburgMD20879
    USA

    T: +1 240 631-3200

    E: [email protected]

    https://www.emergentbiosolutions.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    900

Stocks News & Analysis

stocks

ASX utility share downgraded as electricity prices fall

Falling electricity prices weigh on earnings outlook for utility provider.
stocks

Chart of the Week: AI market leader is now surprisingly cheap

This AI beneficiary may still be one of the market’s most compelling bargains.
stocks

Weekly earnings wrap: Rio Tinto leads the way

A closer look at the key earnings results from the first week of August reporting.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,452.0042.100.45%
CAC 408,724.9155.620.64%
DAX 4026,184.9558.650.22%
Dow JONES (US)54,349.12263.240.49%
FTSE 10010,903.2614.960.14%
HKSE25,530.28385.54-1.49%
NASDAQ26,363.44221.55-0.83%
Nikkei 22565,683.26617.18-0.93%
NZX 50 Index13,958.0639.12-0.28%
S&P 5007,723.5512.97-0.17%
S&P/ASX 2009,271.6041.800.45%
SSE Composite Index3,900.3521.920.57%

Market Movers